Japan stock market week to May 25, 2009
Tokyo bounced back in the week ended May 25. The Nikkei 225 gained 3.4%, to close at the 9,300 level and the Topix Index ended up 2.7%. Investors accepted a report of the steep decline in the January-March Gross Domestic Product positively, seeing that the worst would have been over and expecting a year-on-year improvement in the April-June quarter. January-March GDP plunged to an annualized 15.2%, the sharpest ever decline, due to sluggish exports and a cut in production by Japanese manufacturers. Domestic economy-oriented stocks such as real estate and trading drew buying attention. The pharmaceutical index went up 2.3%, slightly underperforming the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze